| Dr Amber Hope Foreman, PSYD | |
|
564 Crackwillow Ave, Fairhope, AL 36532-0028 | |
| (251) 768-8584 | |
| Not Available |
| Full Name | Dr Amber Hope Foreman |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 564 Crackwillow Ave, Fairhope, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407625833 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 0810008342 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amber Hope Foreman, PSYD 564 Crackwillow Ave, Fairhope, AL 36532-0028 Ph: (251) 768-8584 | Dr Amber Hope Foreman, PSYD 564 Crackwillow Ave, Fairhope, AL 36532-0028 Ph: (251) 768-8584 |
News Archive
Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.
Plastic pollution and disposal of single use plastic packaging is a huge sustainability issue in need of innovative solutions: latest results from the EU-funded project YPACK show that an innovative formulation of active ingredients could allow this biodegradable food packaging to prolong the shelf life of foods and therefore reduce food waste.
In one of the largest studies of its kind, a multinational team led by scientists from deCODE genetics has reported the discovery of common variations at seven new sites in the human genome found to influence obesity.
SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound SM101, which is being developed for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).
› Verified 5 days ago
Dr. Christine S Aiken, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 7 S Bayview St, Fairhope, AL 36532 Phone: 251-478-3044 Fax: 251-476-9055 | |
Dr. Amy Smith Hollimon, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 301 N Summit St, Fairhope, AL 36532 Phone: 251-284-1843 | |
Dr. David S Kantra, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 150 S Church St, Fairhope, AL 36532 Phone: 251-928-5353 Fax: 251-990-4962 | |
France Frederick, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 131 Fairhope Ave, Fairhope, AL 36532 Phone: 251-928-0765 | |
Mr. Christopher Murphree, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 552 Washington Dr, Fairhope, AL 36532 Phone: 479-221-8680 | |
Dr. Cathy J Brumback, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 22787 Us Highway 98, Suite C2, Fairhope, AL 36532 Phone: 251-990-2305 |